Beamr video compression achieves up to 50% improvement for AVs
David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a recent SEC filing, Young acquired 124,500 shares at a price of $0.7975 per share, amounting to a total transaction value of $99,288. This purchase boosts Young’s direct ownership to 205,405 shares.
In addition to his direct holdings, Young also maintains indirect ownership through various entities. The Young-Plaisance Revocable Trust holds 30,985 shares, Family Entities own 10,786 shares, and CorLyst, LLC holds 18,544 shares. These indirect holdings reflect Young’s broader investment strategy within Processa Pharmaceuticals, which currently has a market capitalization of $1.84 million. According to InvestingPro analysis, the company appears undervalued based on its Fair Value model, though investors should note its weak overall financial health score. Subscribers can access 15 additional ProTips and detailed financial metrics for deeper insight into PCSA’s valuation and prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.